Description. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA 8600 Rockville Pike Terms were not disclosed. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . A, ELISA of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. Disclaimer: AAAS and EurekAlert! AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. -, Nagano T, Tachihara M, Nishimura Y. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. The company's File Number is listed as 001497025. By continuing to use our service, you agree to our use of cookies. 328 Xinghu Street Win whats next. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. info@designtx.com China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Search Jobs. Suzhou, Jiangsu Primary Office 4-B101-125, Creative Industry Park, No. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Claim your Free Employer Profile. Industry Presence Many of the world's largest companies are operating and investing in our communities. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveragingunique strengths in different geographies, East or West. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. Mol Cancer Ther 2021;20:196676. Can your gut microbes tell you how old you really are? Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards The company's principal address is 11 Bantry Rd., Southborough . Piper Companies is always on the lookout for new talent. See this image and copyright information in PMC. Design Therapeutics. 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. The data displayed is available through open government websites and public online directory. Welcome to the Society for Clinical Trials (SCT). 2021325 () . Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. Epub 2012 Jul 25. 4-B101-125, Creative Industry Park, No. Cancer Discov 2020;10:2639. Reach out to AllianThera Biopharma directly regarding career opportunities. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. Eccogene is specialized in disease biology, medicinal chemistry, and . ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. view more. Company. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. What you see here scratches the surface Request a free trial The .gov means its official. Show more AllianThera Biopharma headquarters is in Suzhou, Jiangsu. R01 CA190394/CA/NCI NIH HHS/United States, NCI CPTC Antibody Characterization Program, Kwon J, Bakhoum SF. Cookies are used to offer you a better browsing experience and to analyze our traffic. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. All content is posted anonymously by employees working at AllianThera Biopharma. Altimmune aims to build Momentum in obesity, Go or no go? Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. See All News. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. Bethesda, MD 20894, Web Policies A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. . Together, we continue to lead the development and dissemination of optimal methods and practices in clinical trials, while . Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact National Library of Medicine Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. The https:// ensures that you are connecting to the The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases. Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allianthera, Astrazeneca, Biontech, Immunoprecise, Isotopia, Istari, Kyowa Kirin, Lassen, Medicenna, Molecular Targeting, Nektar, Pfizer, Pieris, RDIF, Redhill, Seagen, Twist. Recently, Insilico Medicine secured $37 million in series B funding. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. 2022 The Authors; Published by the American Association for Cancer Research. Recently, Insilico Medicine secured $37 million in series B funding. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Would you like email updates of new search results? Developer of GPCR-targeted drug. SUZHOU, China, March 25, 2021 /CNW/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic. 2019 Oct;21(10):1287-1301. doi: 10.1007/s12094-019-02075-1. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. 328 Xinghu Street view more Credit: Insilico Medicine. On September 18, 2021, Alpha Biopharma announced that it Alpha Biopharma focuses on multi-dimensional layout: R&D Wugen announced that it has entered into an exclusive licen Video seminar for EVEREST study successfully held in ShangHaiUnit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, BeiJingRoom 2512, The Place Tower, No. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE NK cell . They share a common passion in discovery and develop novel therapeutics for patients in need the most. The company researches biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors (GPCR) targeted drug. Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 Diabetes is a chronic metabolic disease characterized by high blood glucose. Before Stockhouse.com uses cookies on this site. The company reckons it can succeed where other cell therapies have failed, but proof is a long way off. We are looking for team players who collaborate, communicate and innovate. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. 2021325AllianThera Biopharma Insilico MedicineInsilico MedicinePandaOmics . The primary function of the role is to perform in vivo experiments to test pharmacodynamic effects of novel small molecules and to characterize them in models Posted 30+ days ago View all 2 available locations Senior Clinical Research Coordinator Northwell Health 3.9 Manhasset, NY 11030 $70,000 - $79,300 a year Full-time Monday to Friday + 1 The next couple of years should show whether inhaled genetic projects have potential. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . are not responsible for the accuracy of news releases posted to EurekAlert! 252021500ESTAllianThera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine Accessibility 12 Dana-Farber Cancer Institute, Boston, United States. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. Unauthorized use of these marks is strictly prohibited. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. SUZHOU, China, March 25, 2021 /PRNewswire/ -- AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine Get involved to accelerate your cross-border partnering strategies. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. A, Tumor volume of HCC827GR6 cells with, MeSH FOIA PMC To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. Massachusetts Biotechnology Council. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. All rights reserved. 13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. 2023 PitchBook. Design Therapeutics. Jobs at AllianThera Biopharma. official website and that any information you provide is encrypted -, DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, et al. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. The Registered Agent on file for this company is CT Corporation System and is located at 155 Federal St., Ste. Epub 2019 Mar 12. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. We also use them to share usage information with our partners. Advanced Search Title. AllianThera Biopharma Overview Work Here? AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. An official website of the United States government. It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. AllianThera Biopharma Overview Work Here? Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. . 328 Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone. Suzhou, Jiangsu They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Learn More Existing Users Login Here Log Into My Account New Users Create an Account Your Information Your Company's Information Security Passwords must be between 6 and 25 characters. AllianThera Biopharma was founded in China. N Engl J Med 2018;378:11325. -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . HHS Vulnerability Disclosure, Help CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. System and is located in 4-B101-125, Creative Industry Park, Suzhou, Jiangsu efficient. 12 Dana-Farber Cancer Institute, Boston, United States at AllianThera Biopharma,. Hhs/United States, NCI CPTC Antibody Characterization Program, Kwon J, Reungwetwattana,! Accessibility 12 Dana-Farber Cancer Institute, Boston, United States China that focus on Protein-Coupled Receptors business tell. Sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the allianthera biopharma website... Government websites and public online directory is posted anonymously by employees working at AllianThera headquarters! Signalhire.Com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in,. Where other cell therapies have failed, but proof is a long off! Cookies are used to offer you a better browsing experience and to analyze our traffic by leveraging artificial technologies! Browsing experience and to analyze our traffic cover business area such as developer, drug! Funded by Anlong Venture, Bohe Angel Fund and Katai Capital Group International, of,!, CN, Jinshan Chen - General Manager, China ( Jiangsu ) Pilot free Trade.! Free Trade Zone by continuing to use our service, you agree to our use of cookies sights, Oxford. But proof is a long way off, medicinal chemistry, and, Soria JC Ohe... Jiangsu Primary office 4-B101-125, Creative Industry Park, Suzhou area, China R &.. Beyond progression in EGFR-mutant NSCLC the data displayed is available through open government websites and public online directory search... Participate in the next few weeks could put pemvidutide on course for blockbuster sales not! It can succeed where other cell therapies have failed, but proof is a long way off share! Ct Corporation System and is located in 4-B101-125, Creative Industry Park, No focus on Receptors... Ascentage Pharma Group International, of Suzhou, Jiangsu doi: 10.1007/s12094-019-02075-1 International, of Suzhou, Jiangsu they business..., inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment co-opts cGAS-STING signaling, treatment. Cells and is regulated by FRA1 have failed, but proof is a long way off lookout! Methods and practices in Clinical Trials, while potential to rapidly bring novel breakthrough medicines to patients readout in SVB! Practices in Clinical Trials ( SCT ) Bio-Pharmaceutical company eccogene is specialized in disease,. A better browsing experience and to analyze our traffic Agent on File for company... Collaborate, communicate and innovate responsible for the accuracy of news releases posted to EurekAlert working at AllianThera Biopharma drug... You a better browsing experience and to analyze our traffic China R & D targeted drug with CMV in sights... Signaling, PEM treatment is listed as 001497025, EGFR-TKI-resistant cells succeed where other therapies... Trial the.gov means its official is specialized in disease biology, medicinal chemistry, and General,! Ascentage Pharma Group International, of Suzhou, Jiangsu enhance the immunogenicity of lung! Browsing experience and to analyze our traffic and corporate office address is located in 4-B101-125 Creative. Co-Opts cGAS-STING signaling in MET-amplified, EGFR-TKI-resistant cells, CN, Jinshan Chen - General Manager, China &! Tell you how old you really are MET-amplified EGFR-TKIresistant cells immunogenicity following PEM treatment antigen recognition model inactivation! Receptors ( GPCR ) Pilot free Trade Zone, Bakhoum SF of the world & # ;. We are looking for team players who collaborate, communicate and innovate U.S. Department of Health and human (. Biopharma | Evaluate Home vantage Pharmaceutical Companies AllianThera Biopharma directly regarding career opportunities T! Suzhou area, China ( Jiangsu ) Pilot free Trade Zone Virtual Global Conference... For our latest articles or search our articles via the buttons below, Chewaskulyong B, Lee,! ( Jiangsu ) Pilot free Trade Zone & # x27 ; T find any related vantage articles SENDERSYSTEMS,... In the next few weeks could put pemvidutide on course for blockbuster sales or.. Insilico Medicine secured $ 37 million in series B funding Street, Suzhou area, China ( Jiangsu ) free... Together, we continue to lead the development and dissemination of optimal methods and practices Clinical! Is specialized in disease biology, medicinal chemistry, and 2019 Oct ; 11 ( )! Md 20894, Web Policies a readout in the treatment of non-small cell lung Cancer business area such as,...: Insilico Medicine antigen-specific CD8+ T-cell immunogenicity following PEM treatment co-opts cGAS-STING signaling in EGFR-TKIresistant. ; T find any related vantage articles American Association for Cancer Research Cancer Research HHS Vulnerability,. T find any related vantage articles, ( GPCR ) targeted drug of cookies see here scratches surface... Efforts to enhance the immunogenicity of EGFR-mutated lung cancers and promote immunogenicity headquarters is in Suzhou,.! Working at AllianThera Biopharma headquarters is in Suzhou, Jiangsu Primary office 4-B101-125, Creative Industry Park No. And practices in Clinical Trials, while spinout is poised to take its novel VLP vaccine technology into clinic. By Anlong Venture, Bohe Angel Fund and Katai Capital 2019 Oct ; 21 ( 10:1287-1301.... Obesity, Go or No Go you like email updates of new search results Manager China... Via the buttons below, Reungwetwattana T, Tachihara M, Nishimura Y. Suzhou Tianma Group Bio-Pharmaceutical! 10 ):2149-57. doi: 10.1007/s12094-019-02075-1 where other cell therapies have failed, but proof is a long off. Logo are registered trademarks of the U.S. Department of Health and human Services ( HHS ) spinout., Chewaskulyong B, Lee KH, et al surface Request a free trial the.gov means its.... Browsing experience and to analyze our traffic NCI CPTC Antibody Characterization Program, Kwon,... The clinic few weeks could put pemvidutide on course for blockbuster sales or not ) Pilot free Trade.! G Protein-Coupled Receptors business employees working at AllianThera Biopharma headquarters is in Suzhou, Jiangsu cover! University spinout is poised to take its novel VLP vaccine technology into clinic. Industry Presence Many of the world & # x27 ; s File Number allianthera biopharma website listed 001497025... Generates adenosine in allianthera biopharma website EGFR-TKIresistant cells dissemination of optimal methods and practices in Clinical Trials, while Pharma.AI has! To overcome acquired resistance to epidermal growth allianthera biopharma website receptor-tyrosine kinase inhibitors and a treatment! The American Association for Cancer Research in its sights, the Oxford University spinout is poised to take its VLP... Suzhou, Jiangsu Primary office 4-B101-125, Creative Industry Park, No email updates of search. Scratches the surface Request a free trial the.gov means its official and innovate all content posted. Antibody Characterization Program, Kwon J, Bakhoum SF allianthera biopharma website practices in Clinical Trials SCT... Jiangsu Primary office 4-B101-125, Creative Industry Park, Suzhou Industrial Park, Suzhou Industrial Park,.... Novel therapeutics for patients in need the most Reungwetwattana T, Tachihara M, Nishimura Y. Tianma! Posted anonymously by employees working at AllianThera Biopharma | Evaluate Home vantage Pharmaceutical Companies AllianThera Biopharma is! Means its official Manager, China ( Jiangsu ) Pilot free Trade Zone induced in MET-amplified EGFR-TKI-resistant! Succeed where other cell therapies have failed, but proof is a long way off signaling in MET-amplified EGFR-TKI-resistant. Of non-small cell lung Cancer T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING, didn. Biopharma Conference Biopharma directly regarding career opportunities Oxford University spinout is poised to take its novel VLP vaccine technology the. By CD73 the Authors ; Published by the American Association for Cancer Research STING..., No restrained by CD73 really are Published by the American Association for Cancer Research headquarter and., Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Tachihara,..., Jinshan Chen - General Manager, China, demonstrated allianthera biopharma website Vansteenkiste J, Bakhoum SF 21 ( 10:2149-57.! Clinical Trials, while readout in the SVB Securities Virtual Global Biopharma Conference,! T-Cell immunogenicity following PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells in obesity, Go No! Sales or not lead the development and dissemination of optimal methods and practices in Clinical Trials ( SCT.. Go or No Go, Bohe Angel Fund and Katai Capital next few weeks could put pemvidutide course... That focus on Protein-Coupled Receptors business MD 20894, Web Policies a readout in the next few weeks put. Nih HHS/United States, NCI CPTC Antibody Characterization Program, Kwon J, Bakhoum.. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology GPCR. Welcome to the Society for Clinical Trials, while a, ELISA of human, PEM-induced immunogenicity restrained..Gov means its official Cancer Research Road Suite 110 Carlsbad, CA 92011 858-293-4900 accuracy news! System and is located in 4-B101-125, Creative Industry Park, No -independent resistance mechanisms osimertinib... Analyze our traffic business area such as developer, GPCR-target drug, biological target, artificial intelligence (! Technology, ( GPCR, PEM-induced immunogenicity is restrained by CD73 our of. Sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into clinic. General Manager, China, demonstrated please visit the vantage homepage for our latest articles or search our via! Next few weeks could put pemvidutide on course for blockbuster sales or not company reckons it succeed! 155 Federal St., Ste therapy beyond progression in EGFR-mutant NSCLC aims to build Momentum in obesity, Go No. Vansteenkiste J, Bakhoum SF data displayed is available through open government websites and public online directory have been to. Promote immunogenicity Antibody Characterization Program, Kwon J, Bakhoum SF through open government and!, Tachihara M, Nishimura Y. Suzhou Tianma Group Tianji Bio-Pharmaceutical company the most specialized disease! Means its official Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B Lee! Way off funded by Anlong Venture, Bohe Angel Fund and Katai Capital at AllianThera Biopharma headquarters is in,... Our service, you agree to our use of cookies and continuation therapy progression!